Plain-English translation of NCT07551050 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a newer breast cancer medication called sacituzumab govitecan in Chinese patients with advanced, triple-negative breast cancer that has worsened despite initial treatment. Researchers want to understand how this medication affects patients' everyday quality of life — including physical symptoms, emotional well-being, and daily activities — compared to standard chemotherapy options. About 300 patients will participate across multiple hospitals.
Many patients with advanced triple-negative breast cancer have limited treatment options after their first therapy stops working. This study exists to see whether the new medication might offer better quality of life and symptom control than traditional chemotherapy, helping doctors and patients make informed choices about treatment.
You likely qualify if…
You likely don't qualify if…
You will visit a hospital or clinic to receive either the new medication (sacituzumab govitecan) or standard chemotherapy chosen by your doctor based on your preferences and medical needs. Throughout the study, you'll regularly complete questionnaires on an electronic device about your symptoms, side effects, and how the treatment is affecting your daily life. The study will track how well your cancer responds and how you feel physically and emotionally over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Sponsor
Fudan University
Enrollment target
~300 participants
Started
May 2026
Primary completion
April 2029
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Biyun Wang Professor
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.